Literature DB >> 6103577

Biological and behavioral consequences of alterations in monoamine oxidase activity.

D L Murphy, N H Kalin.   

Abstract

Monoamine oxidase (MAO) has many intraneuronal regulatory metabolic functions as well as detoxifying properties. Inhibition of the enzyme leads to rapid changes in the cellular concentrations of neurotransmitter amines and in the balance between different amines in neurons. Longer term alterations in MAO activity are accompanied by secondary, adaptational changes in neurotransmitter-related receptors, other enzymes, and additional cell functions in brain and other tissues. In addition, MAO inhibition is accompanied by marked changes in the sensitivity of the organism to some dietary constituents (e.g., tyramine, tryptophan, and other amines and amine precursors) as well as to many drugs (e.g., sympathomimetics, opiates, reserpine, and caffeine). While nearly complete MAO inhibition has been said to be required for direct behavioral changes to occur, partial MAO inhibition (reductions of 25-75 percent in enzyme activity) or selective inhibition of either the MAO-A or MAO-B form of the enzyme-especially after longer term inhibitor administration-lead to readily demonstrable alterations in the sensitivity of both animals and man to a variety of exogenous agents, and are also associated with a number of biological changes, including those involving neuroendocrine, blood pressure, and sleep mechanisms. These changes in cellular mechanisms and physiological functions may provide models for evaluating the significance of moderate (40 percent) mean reductions in platelet MAO activity found in chronic schizophrenic patients and some other psychiatric patient populations. The basic principle underlying these models is that MAO inhibition leads to impaired regulation in many neurotransmitter systems and other cellular functions, yielding consquent deficits in the attenuation of responses to exogenous stimuli and to endogenous psychobiological changes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6103577     DOI: 10.1093/schbul/6.2.355

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  7 in total

1.  Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.

Authors:  R Heintz; D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Monoamine oxidases A and B are differentially regulated by glucocorticoids and "aging" in human skin fibroblasts.

Authors:  S B Edelstein; X O Breakefield
Journal:  Cell Mol Neurobiol       Date:  1986-06       Impact factor: 5.046

3.  Screen for MAOA mutations in target human groups.

Authors:  D E Schuback; E L Mulligan; K B Sims; E A Tivol; B D Greenberg; S F Chang; S L Yang; Y C Mau; C Y Shen; M S Ho; N H Yang; M G Butler; S Fink; C E Schwartz; F Berlin; X O Breakefield; D L Murphy; Y P Hsu
Journal:  Am J Med Genet       Date:  1999-02-05

4.  Human monoamine oxidase A gene determines levels of enzyme activity.

Authors:  G S Hotamisligil; X O Breakefield
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

5.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 6.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

7.  Effect of a controlled food-chain mediated exposure to cadmium and arsenic on oxidative enzymes in the tissues of rats.

Authors:  Theresa Ezedom; Samuel O Asagba
Journal:  Toxicol Rep       Date:  2016-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.